[BFAD BUREAU CIRCULAR NO. 03, S. 2004, March 26, 2004]

GUIDELINES FOR THE REGISTRATION AND PERFORMANCE VALIDATION OF METHAMPHETAMINE (MET)/TETRAHYDROCANNABINOL (THC) DRUG SCREENING TEST KITS

For the information and guidance of all concerned, drug screening test kits are now subject to the licensing and regulation requirements of the Bureau of Food and Drugs (BFAD) in accordance with the Comprehensive Dangerous Drugs Act of 2002 and RA 3720 as amended.

In consonance with the Administrative Order No. 134, s. 2004, the East Avenue Medical Center (EAMC) has been designated as the National Reference Laboratory (NRL) that will conduct performance evaluation of the Drug Screening Test Kits and Reagents.

EAMC will initially evaluate drug screening test kits containing MET and THC using non-instrumental analysis only. In the meantime while EAMC is building up its capability, the certificates of validated drug screening test kits (MET/THC) issued by the Dangerous Drugs Board is extended until 15 April 2004, while the certificates of validated drug screening test kits for Opiates, Cocaine and Barbiturates, among others, issued by the Dangerous Drugs Board are indefinitely extended until further notice.

Any violation of the guidelines herein provided shall be subject to appropriate sanctions by BFAD.

For information and compliance by all concerned.

Adopted: 26 March 2004

(SGD.) PROF. LETICIA-BARBARA B. GUTIERREZ, M.S. *Director*

